This company has been marked as potentially delisted and may not be actively trading. RXi Pharmaceuticals (RXII) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RXII vs. ELYM, HILS, EGRX, MRNS, ALLK, CARA, NNVC, ME, IBIO, and GLYCShould you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include Eliem Therapeutics (ELYM), Hillstream BioPharma (HILS), Eagle Pharmaceuticals (EGRX), Marinus Pharmaceuticals (MRNS), Allakos (ALLK), Cara Therapeutics (CARA), NanoViricides (NNVC), 23andMe (ME), iBio (IBIO), and GlycoMimetics (GLYC). These companies are all part of the "medical" sector. RXi Pharmaceuticals vs. Its Competitors Eliem Therapeutics Hillstream BioPharma Eagle Pharmaceuticals Marinus Pharmaceuticals Allakos Cara Therapeutics NanoViricides 23andMe iBio GlycoMimetics Eliem Therapeutics (NASDAQ:ELYM) and RXi Pharmaceuticals (NASDAQ:RXII) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings. Is ELYM or RXII more profitable? Eliem Therapeutics has a net margin of 0.00% compared to RXi Pharmaceuticals' net margin of -4,990.20%. Eliem Therapeutics' return on equity of -47.03% beat RXi Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% RXi Pharmaceuticals -4,990.20%-412.15%-179.54% Which has more volatility & risk, ELYM or RXII? Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Comparatively, RXi Pharmaceuticals has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Do insiders & institutionals believe in ELYM or RXII? 69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 9.6% of RXi Pharmaceuticals shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 1.0% of RXi Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings & valuation, ELYM or RXII? RXi Pharmaceuticals has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-2.42RXi Pharmaceuticals$10K1,051.20-$12.45M-$4.20-0.57 Does the media favor ELYM or RXII? In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 equaled RXi Pharmaceuticals'average media sentiment score. Company Overall Sentiment Eliem Therapeutics Neutral RXi Pharmaceuticals Neutral SummaryEliem Therapeutics beats RXi Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get RXi Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXII vs. The Competition Export to ExcelMetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.51M$793.00M$5.53B$9.04BDividend YieldN/A4.84%5.24%4.02%P/E Ratio-0.571.3727.6320.25Price / Sales1,051.20230.41417.36118.60Price / CashN/A23.4436.8958.07Price / Book3.126.328.035.67Net Income-$12.45M-$27.99M$3.18B$249.21M RXi Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXIIRXi PharmaceuticalsN/A$2.40-3.2%N/A+313.2%$10.51M$10K-0.57N/AELYMEliem TherapeuticsN/A$1.24+5.1%N/A-81.3%$36.89MN/A-2.349HILSHillstream BioPharmaN/A$1.80+2.4%N/A-44.0%$31.73MN/A-2.501EGRXEagle PharmaceuticalsN/A$2.36-18.6%N/A-45.5%$30.65M$257.55M0.00100Gap DownMRNSMarinus Pharmaceuticals2.3608 of 5 stars$0.55-0.2%$3.92+613.3%-54.6%$30.32M$30.99M-0.22110News CoverageALLKAllakos2.8855 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190CARACara Therapeutics0.3513 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumeNNVCNanoViricides1.1261 of 5 stars$1.42+1.7%N/A-20.5%$22.90MN/A-1.9820ME23andMeN/A$0.50-35.3%N/A-94.1%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeIBIOiBio2.0678 of 5 stars$0.75-1.5%$4.30+471.8%-63.0%$12.44M$375K0.00100GLYCGlycoMimetics1.1871 of 5 stars$0.16-6.6%N/A-99.4%$10.00M$10K-0.3450High Trading Volume Related Companies and Tools Related Companies ELYM Alternatives HILS Alternatives EGRX Alternatives MRNS Alternatives ALLK Alternatives CARA Alternatives NNVC Alternatives ME Alternatives IBIO Alternatives GLYC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXII) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share RXi Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
